Therapy of steroid-resistant graft-versus-host disease (GVHD) with ant
ibodies to T cells or cytokines is of limited value because GVHD is me
diated by a pleomorphic group of effective cells and cytokines. CBL-1,
a murine monoclonal antibody, recognises an antigen on activated T ce
lls, B cells, and natural killer cells. We administered CBL-1 to ten p
atients with grade III or IV steroid-resistant GVHD. Complete remissio
ns occurred in five cases and partial remissions in four. The organ sy
stem(s) affected by GVHD was not a predictor of response. CBL-1 was we
ll tolerated and did not exacerbate post-transplant immunodeficiency.
Our findings support the use of CBL-1 in primary prophylaxis for GVHD.